Gilead Sciences Commences Tender Offer to Acquire Arcellx for $115.00 Cash Plus $5.00 CVR Per Share

summarizeSummary

Gilead Sciences, through its subsidiary, has formally launched its tender offer to acquire all outstanding shares of Arcellx, Inc. for $115.00 per share in cash, plus a contingent value right of $5.00 per share, following the definitive agreement announced on February 23, 2026.

check_boxKey Events

• Tender Offer Commenced

  Gilead Sciences' subsidiary, Ravens Sub, Inc., has formally commenced a tender offer to acquire all outstanding shares of Arcellx, Inc.

• Acquisition Terms Detailed

  Shareholders are offered $115.00 per share in cash, plus one Contingent Value Right (CVR) for $5.00, contingent on Arcellx's anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion in cumulative worldwide sales by December 31, 2029.

• Board Unanimously Recommends Offer

  Arcellx's Board of Directors unanimously recommends that shareholders accept the offer and tender their shares.

• Follows Prior Acquisition Announcement

  This tender offer operationalizes the definitive agreement for the acquisition by Gilead Sciences, Inc. that was publicly announced on February 23, 2026.

auto_awesomeAnalysis

This SC TO-T filing marks the formal commencement of Gilead Sciences' tender offer to acquire all outstanding shares of Arcellx, Inc., operationalizing the definitive agreement announced on February 23, 2026. The offer provides Arcellx shareholders with $115.00 per share in cash, plus a Contingent Value Right (CVR) of $5.00 per share, contingent on the anitocabtagene autoleucel (anito-cel) product achieving cumulative worldwide sales exceeding $6.0 billion by December 31, 2029. This represents a substantial premium over Arcellx's trading price prior to the initial announcement and is near its 52-week high, reflecting the significant value offered. The unanimous recommendation from Arcellx's Board of Directors and the tender agreements from key insiders and institutional investors (representing approximately 10.3% of shares) indicate strong support for the acquisition. This transaction is a strategic move for Gilead, building on its existing collaboration with Arcellx, and will result in Arcellx becoming a wholly-owned subsidiary, with its shares delisted from Nasdaq.